What they were paid
Adaptimmune Therapeutics Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2024 | $26,250 | $0 | $147,636 | $0 | $173,886 |
| FY2023 | $22,500 | — | $59,754 | — | $82,254 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Adaptimmune Therapeutics PLC DEF 14A filed April 25, 2025, accession 0001104659-25-039042, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2024Adaptimmune Therapeutics pays directors a $40,000 cash retainer.
Committees
FY2024 · as the proxy prints themNominating/Governance · Research and Development
The rest of the Adaptimmune Therapeutics board
FY2024 · as the company reported each| Director | Role | FY2024 total |
|---|---|---|
| Adrian Rawcliffe | Director | $0 |
| Ali Behbahani | Independent Director | $152,086 |
| Andrew Allen | Independent Director | $140,123 |
| David M. Mott | Chair of the Board | $204,195 |
| Garry Menzel | Independent Director | $144,659 |
| John Furey | Independent Director | $142,623 |
| Kristen Hege | Independent Director | $141,524 |
| Lawrence M. Alleva | Independent Director | $156,566 |
The full Adaptimmune Therapeutics compensation record
free company briefThis page is one director within Adaptimmune Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat